Intrexon | XON - Current Assets


Intrexon reported $23.72M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Amgen USD 34.96B 3.49B Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
MannKind USD 245.71M 5.45M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Veracyte USD 574.78M 52.6M Jun/2026
Xencor USD 523.21M 40.36M Jun/2026